Abbott Laboratories (ABT)

US — Healthcare Sector
Peers: NVO  MRK  TMO  NVS  BSX  MDT  SYK  ISRG  UNH  GILD 

Automate Your Wheel Strategy on ABT

With Tiblio's Option Bot, you can configure your own wheel strategy including ABT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles
ABT
Published: March 09, 2026 by: Seeking Alpha
Sentiment: Positive

Abbott Laboratories (ABT) remains a Buy, with the stock undervalued at $109.56 despite recent execution missteps and Nutrition segment weakness. Core Devices and Diagnostics segments continue to deliver high single-digit sales growth and double-digit EPS growth, supporting the investment thesis. Nutrition remains a key risk, but management expects a turnaround in the second half; Exact Sciences acquisition could add a new high-growth vertical.

Read More
image for news Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles
Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles
ABT
Published: March 09, 2026 by: Seeking Alpha
Sentiment: Positive

Abbott Laboratories (ABT) remains a Buy, with the stock undervalued at $109.56 despite recent execution missteps and Nutrition segment weakness. Core Devices and Diagnostics segments continue to deliver high single-digit sales growth and double-digit EPS growth, supporting the investment thesis. Nutrition remains a key risk, but management expects a turnaround in the second half; Exact Sciences acquisition could add a new high-growth vertical.

Read More
image for news Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
ABT
Published: March 04, 2026 by: Zacks Investment Research
Sentiment: Positive

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Read More
image for news Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Best Dividend Aristocrats For March 2026
ABBV, ABT, ADM, ADP, AFL, ALB, AMCR, AOS, APD, ATO, BDX, BEN, BRO, CAH, CAT, CHD, CHRW, CINF, CL, CLX, CTAS, DOV, ECL, ED, EMR, BF-A, BF-B, ERIE, ES, EXPD, FAST, FDS, FRT, GD, GPC, GWW, HRL, IBM, ITW, JNJ, KMB, KO, KVUE, LIN, LOW, MCD, MDT, MKC, NDSN, NEE, NOBL, NUE, O, PEP, PG, PNR, PPG, ROP, SHW, SJM, SPGI, SPY, SWK, SYY, TGT, TROW, WMT, WST, XOM
Published: February 27, 2026 by: Seeking Alpha
Sentiment: Positive

The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) is up 9.39% YTD in 2026, decisively outperforming SPY's 1.08%. Dividend Aristocrats are regaining momentum after a weak 2025, with 55 outpacing SPY and 39 posting double-digit gains this year already. Dividend growth is lagging, with 2026's average increase currently at 3.22%, below last year's trend and potentially signaling headwinds.

Read More
image for news Best Dividend Aristocrats For March 2026
Intuitive Surgical or Abbott: Which MedTech Stock Is a Better Bet Now?
ABT, ISRG
Published: February 26, 2026 by: Zacks Investment Research
Sentiment: Positive

Both ISRG and ABT closed 2025 on a strong note, but Intuitive Surgical's surging procedure growth and innovation may give it the edge for long-term gains.

Read More
image for news Intuitive Surgical or Abbott: Which MedTech Stock Is a Better Bet Now?
Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time
ABT
Published: February 25, 2026 by: The Motley Fool
Sentiment: Positive

Abbott Labs has raised its dividends for 54 consecutive years. The company expects earnings growth from its acquisition of Exact Sciences.

Read More
image for news Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time
Abbott Labs: A Boring Dividend Machine That Could Quietly Make You Rich
ABT
Published: February 23, 2026 by: The Motley Fool
Sentiment: Positive

Abbott Laboratories' business, if not exciting, is resilient and consistent. The company is a leader in multiple markets and has attractive growth avenues.

Read More
image for news Abbott Labs: A Boring Dividend Machine That Could Quietly Make You Rich
Exact Sciences Stockholders Approve Acquisition by Abbott
ABT, EXAS
Published: February 20, 2026 by: Business Wire
Sentiment: Neutral

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Scie.

Read More
image for news Exact Sciences Stockholders Approve Acquisition by Abbott
Abbott declares 409th consecutive quarterly dividend
ABT
Published: February 20, 2026 by: PRNewsWire
Sentiment: Neutral

ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.

Read More
image for news Abbott declares 409th consecutive quarterly dividend
BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
ABT, BSX
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive

Abbott edges out Boston Scientific in the MedTech faceoff, with valuation appeal, strong CGM momentum and strategic deals boosting its investment case.

Read More
image for news BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
ABT
Published: February 18, 2026 by: Zacks Investment Research
Sentiment: Positive

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key
ABT
Published: February 17, 2026 by: GlobeNewsWire
Sentiment: Neutral

LISTING LINK: https://www.premiersothebysrealty.com/single-family/mfr/a4681242/6610-gulf-of-mexico-drive-longboat-key-fl-34228 DROPBOX: https://tours.coastalhomephotography.net/public/vtour/display/2359971?idx=1#!/nav/gallery PHOTO CREDIT: Coastal Home Photography LONGBOAT KEY, Fla.

Read More
image for news Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key
Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next?
ABT
Published: February 12, 2026 by: 24/7 Wall Street
Sentiment: Positive

Abbott Laboratories just paid its quarterly dividend of $0.63 per share on February 13, 2026, marking a 6.8% increase from the prior quarterly rate.

Read More
image for news Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next?
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
ABT
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Positive

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Read More
image for news Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Abbott recalls glucose sensors after seven deaths linked to faulty readings
ABT
Published: February 04, 2026 by: Reuters
Sentiment: Negative

Abbott has recalled certain glucose monitoring sensors after reports linked the devices to seven deaths and 860 serious injuries, the U.S. health regulator said on Wednesday.

Read More
image for news Abbott recalls glucose sensors after seven deaths linked to faulty readings
NVST or ABT: Which Is the Better Value Stock Right Now?
ABT, NVST
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive

Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?

Read More
image for news NVST or ABT: Which Is the Better Value Stock Right Now?
Abbott: Long-Term Investment Opportunity For Dividend Growth Investors
ABT
Published: February 02, 2026 by: Seeking Alpha
Sentiment: Positive

In reality, Abbott Laboratories is actually a Dividend Aristocrat – a vaunted status reserved for companies that have increased dividends for at least 25 consecutive years. ABT grew its revenue from $20.8 billion in FY 2016 to $44.3 billion in FY 2025. That's a compound annual growth rate of 8.8%. Abbott Laboratories has a great financial position. The long-term debt/equity ratio is 0.3, while the interest coverage ratio is 17.

Read More
image for news Abbott: Long-Term Investment Opportunity For Dividend Growth Investors
10 Highest Rated Dividend Kings For Generations Of Income
ABBV, ABM, ABT, ADM, BDX, BKH, KMB, KO, MO, NWN, PG, PPG, SPGI, SWK, TGT, WMT
Published: January 29, 2026 by: Seeking Alpha
Sentiment: Positive

My top 10 Dividend Kings list prioritizes reliability, dividend safety, and attractive valuation for long-term, generational income. Selection criteria include payout ratios under 70%, strong dividend safety/growth grades, and favorable Quant, SA, and Wall Street ratings. ABM Industries leads with a low 31% payout ratio, 2.5% yield, B- safety/growth, and an A- valuation grade despite a Hold Quant rating.

Read More
image for news 10 Highest Rated Dividend Kings For Generations Of Income
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
ABT
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Abbott (ABT) is a Top-Ranked Value Stock: Should You Buy?
ABT
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Abbott (ABT) is a Top-Ranked Value Stock: Should You Buy?
Is The Fall In Abbott Stock Justified?
ABT
Published: January 23, 2026 by: Forbes
Sentiment: Neutral

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, aligning with expectations, while the total annual adjusted EPS reached $5.15, indicating a 10% growth.

Read More
image for news Is The Fall In Abbott Stock Justified?
Abbott Laboratories Raised Prices, Prompting Sales Slump
ABT
Published: January 22, 2026 by: WSJ
Sentiment: Negative

The medical-products maker's shares tumbled after its quarterly profit and sales underwhelmed investors.

Read More
image for news Abbott Laboratories Raised Prices, Prompting Sales Slump
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
ABT
Published: January 22, 2026 by: Seeking Alpha
Sentiment: Neutral

Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript

Read More
image for news Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Jobless Claims Come in Slightly Higher
ABT, COF, FCX, GDP, GE, INTC, ISRG, PG
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Negative

Jobless Claims Come in Slightly Higher.

Read More
image for news Jobless Claims Come in Slightly Higher
Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results
ABT, BNO, DBO, GUSH, IEO, OIH, OIL, PXJ, UCO, USO, XOP
Published: January 22, 2026 by: Benzinga
Sentiment: Negative

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Thursday.

Read More
image for news Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results
Jobless Claims Stay Low at +200K, Q3 GDP Up to +4.4%
ABT, COF, FCX, GDP, GE, INTC, ISRG, PG
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive

Weekly Jobless Claims continue to portray a labor market cruising along at a healthy low rate of unemployment claims.

Read More
image for news Jobless Claims Stay Low at +200K, Q3 GDP Up to +4.4%
Abbott's Q4 Earnings Meet Estimates, Revenues Miss, Stock Falls
ABT
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Negative

ABT's Q4 earnings meet estimates but revenues miss, sending shares down as strong device growth is offset by weaker nutrition and diagnostics sales.

Read More
image for news Abbott's Q4 Earnings Meet Estimates, Revenues Miss, Stock Falls
Abbott (ABT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
ABT
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Read More
image for news Abbott (ABT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Abbott (ABT) Matches Q4 Earnings Estimates
ABT
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive

Abbott (ABT) came out with quarterly earnings of $1.5 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $1.34 per share a year ago.

Read More
image for news Abbott (ABT) Matches Q4 Earnings Estimates
Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?
ABT
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Positive

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Read More
image for news Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?

About Abbott Laboratories (ABT)

  • IPO Date 1980-03-17
  • Website https://www.abbott.com
  • Industry Medical - Devices
  • CEO Robert Ford
  • Employees 114000

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.